Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2022-002568-62
    Sponsor's Protocol Code Number:AVB-PGRN-001
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2022-12-05
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2022-002568-62
    A.3Full title of the trial
    A Phase 1/2 Open-Label, Ascending Dose, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of AVB-101 Administered by Bilateral Intrathalamic Infusion in Subjects With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
    Studio di fase 1/2, in aperto, a dosi crescenti, multicentrico volto a valutare la sicurezza e l’efficacia preliminare di AVB-101 somministrato mediante infusione intratalamica bilaterale in soggetti affetti da demenza frontotemporale con mutazioni della progranulina (FTDGRN)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to test whether AVB-101 is both safe and efficacious in a subpopulation of genetically defined FTD patients that currently have no other treatment options
    Uno studio per verificare se AVB-101 sia sicuro ed efficace in una sottopopolazione di pazienti con FTD geneticamente definiti che attualmente non hanno altre opzioni di trattamento
    A.3.2Name or abbreviated title of the trial where available
    Ph1/2 study of AVB-101 in Subjects with Frontotemporal Dementia with Progranulin Mutations (FTD-GRN)
    Studio di Fase 1/2 su AVB-101 in soggetti con FTD-GRN
    A.4.1Sponsor's protocol code numberAVB-PGRN-001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAVIADOBIO LTD
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAviadoBio Limited
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationMedpace
    B.5.2Functional name of contact pointClinical Trial Management
    B.5.3 Address:
    B.5.3.1Street AddressVia Olona 2
    B.5.3.2Town/ cityMilan
    B.5.3.3Post code20123
    B.5.3.4CountryItaly
    B.5.4Telephone number+390283413400
    B.5.6E-mailS.Zambruno@Medpace.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEMA/OD/0000068610
    D.3 Description of the IMP
    D.3.1Product nameRecombinant AAV-9 vector expressing the human progranulin protein
    D.3.2Product code [AVB-101]
    D.3.4Pharmaceutical form Solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntracerebral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.2Current sponsor codeAVB-101
    D.3.9.4EV Substance CodeSUB296517
    D.3.10 Strength
    D.3.10.1Concentration unit g gram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Yes
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product Yes
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms Yes
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
    Demenza Frontotemporale con Mutazioni della Progranulina (FTDGRN)
    E.1.1.1Medical condition in easily understood language
    Dementia
    Demenza
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10068968
    E.1.2Term Frontotemporal dementia
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the safety and tolerability of a one-time, bilateral, intrathalamic administration of AVB-101 in subjects with FTD-GRN.
    Valutare la sicurezza e la tollerabilità di una singola somministrazione intratalamica bilaterale di AVB-101 in soggetti con FTD-GRN.
    E.2.2Secondary objectives of the trial
    To evaluate the preliminary clinical and biomarker measures of efficacy of a one-time, bilateral, intrathalamic administration of AVB-101 in subjects with FTD-GRN.
    Valutare le misure cliniche preliminari e dei biomarcatori di efficacia di una somministrazione intratalamica bilaterale una tantum di AVB-101 in soggetti con FTD-GRN.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Subjects will be eligible to be included in the study if all of the following criteria apply:
    1. Are male or female, 30 to 75 years of age, inclusive, at Screening;
    2. Are carriers of a pathogenic granulin (GRN) mutation as confirmed by a Sponsor approved genetic test;
    3. Have frontotemporal dementia (FTD) as evidenced by Clinical Dementia Rating (CDR) + National Alzheimer’s Coordinating Center (NACC) frontotemporal lobar degeneration
    (FTLD) global score of 0.5, 1.0, or 2.0;
    4. Have presence of 1 or more of the criteria for diagnosis of possible behavioral variant FTD or primary progressive aphasia;
    5. Have a thalamic volume of ¿5.0 cm3 on each side on Screening magnetic resonance imaging (MRI);
    6. For women of childbearing potential, must have a negative serum pregnancy test at Screening, a negative urine dipstick, and not be breastfeeding within 2 weeks prior to treatment;
    7. Are willing to practice a highly effective birth control method as outlined in the Protocol if the subject or partner is of childbearing potential;
    8. Able and willing to comply with all procedures and the study visit schedule as outlined in the Protocol;
    9. Able and willing to give written informed consent prior to study participation, and agree to designate a legal representative to act on their wishes to continue participation should they
    lose capacity to consent at some point during the study; and
    10. Have an identified, informed study partner who is able and willing to support the subject’s participation in the study and to provide assessments of the subject during the study (separate, written informed consent to be obtained from the study partner for their participation, where required to do so by the relevant country’s competent authorities).
    I soggetti saranno idonei ad essere inclusi nello studio se si applicano tutti i seguenti criteri:
    1. Soggetti di sesso maschile o femminile, di età compresa tra 30 e 75 anni inclusi, allo screening;
    2. Essere portatori di una mutazione patogena della granulina (GRN) come confermato da un test genetico approvato dallo sponsor;
    3. Presentare demenza frontotemporale (FTD) evidenziata dalla valutazione clinica della demenza (CDR) + punteggio globale della degenerazione frontotemporale lobare (FTLD) secondo il Centro coordinatore nazionale Alzheimer (NACC) pari a 0,5, 1,0 o 2.0;
    4. Presentare 1 o più criteri per la diagnosi di possibile variante comportamentale della FTD o afasia primaria progressiva;
    5. Presentare un volume talamico di > o = 5,0 cm3 su ciascun lato allo screening con la risonanza magnetica per immagini (RMI);
    6. Per le donne in età fertile, devono presentare un test di gravidanza sul siero negativo allo screening, una striscia reattiva urinaria negativa e non devono allattare al seno nelle 2 settimane precedenti il trattamento;
    7. Disponibile ad adottare un metodo contraccettivo altamente efficace, come indicato nel Protocollo, se il soggetto o la partner è potenzialmente fertile;
    8. Essere in grado e disposti a rispettare tutte le procedure e il programma delle visite dello studio, come indicato nel protocollo;
    9. Essere in grado e disposto a fornire il consenso informato scritto prima della partecipazione allo studio e accettare di designare un rappresentante legale che agisca per proprio conto per proseguire la partecipazione, se il soggetto dovesse perdere la capacità di fornire il proprio consenso a un certo punto durante lo studio; e
    10. Disporre di un partner dello studio identificato e informato in grado e disponibile a supportare la partecipazione del soggetto durante lo studio e a fornire delle valutazioni sul soggetto durante lo studio (sarà ottenuto un consenso informato separato, scritto, dal partner dello studio per la relativa partecipazione, ove richiesto dalle rilevanti autorità competenti del Paese).
    E.4Principal exclusion criteria
    Subjects will be excluded from the study if any of the following criteria apply:
    1. Have a classification of the mutation in the GRN gene as “not pathogenic,” “likely benign variant,” or “benign variant”;
    2. Have severe dementia, defined as CDR + NACC FTLD global score of 3.0, or other symptoms that preclude the ability to comply with study procedures and/or pose unacceptable safety risk
    to the subject;
    3. Have any concurrent disease that may cause cognitive impairment unrelated to mutations in the GRN gene, such as other causes of dementia, neurosyphilis, hydrocephalus, stroke, small
    vessel ischemic disease, uncontrolled hypothyroidism, or vitamin B12 deficiency;
    4. Have a clinically significant abnormality on MRI at Screening considered to be a contraindication to intrathalamic infusion;
    5. Have a surgically significant pattern of brain atrophy on MRI at Screening that in the determination of the neurosurgeon interferes with planned neurosurgical trajectory;
    6. Have had previous treatment with any gene or cell therapy;
    7. Have had previous treatment with any investigational medicinal product within 60 days or
    5 half-lives (whichever is longer) prior to study drug treatment;
    8. Have had a concomitant disease, any clinically significant laboratory abnormality, or treatment which, in the opinion of the Investigator, may pose an unacceptable safety risk to the subject
    or interfere with study conduct or the subject's ability to comply with study procedures;
    9. Have a malignancy within 5 years of Screening, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated;
    10. Have any contraindications to MRI as per local guidelines;
    11. Have any contraindications to gadolinium-based contrast agents per local guidelines;
    12. Have any contraindications to general anesthesia for a period of up to 10 hours and/or cardiopulmonary disorders that would result in higher American Society of Anesthesiology
    risk classification;
    13. Have any contraindications to lumbar puncture as per local guidelines;
    14. Have been hospitalized for any major medical or surgical procedure involving general anesthesia within 12 weeks of Screening or planned procedure during the study;
    15. Are using anticoagulants at Screening, or will have an anticipated need during the period of treatment. Antiplatelet therapies are acceptable concomitant medications if they can be
    stopped at least 48 hours prior to treatment;
    16. Have a history of previous serious or recent Coronavirus Disease 2019 (COVID-19) as defined by (1) any history of hospitalization for severe illness at any time, (2) any history of significant respiratory symptoms at any time, or (3) any pre-symptomatic or mildly symptomatic COVID-19 positivity within 12 weeks prior to planned treatment;
    17. Have a positive drug screen for drugs of abuse;
    18. Have a history of substance abuse disorder;
    19. Have the presence of an implanted deep brain stimulation device, ventriculoperitoneal or other cerebrospinal fluid shunt, or other implanted device;
    20. Have evidence of suicide risk, as assessed by the Columbia-Suicide Severity Rating Scale, defined as either a suicide attempt within 6 months prior to Screening or have a significant risk of suicide as judged by the Investigator; or
    21. Have a known or suspected intolerance or hypersensitivity to the study drug or any of the stated ingredients.
    I soggetti saranno esclusi dallo studio se si applica uno qualunque dei seguenti criteri:
    1. Presentare classificazione della mutazione nel gene GRN come “non patogena”, “probabile variante benigna” o “variante benigna”;
    2. Presentare demenza grave, definita come punteggio globale CDR + NACC FTLD pari a 3,0, o altri sintomi che precludano la capacità di attenersi alle procedure dello studio e/o pongano un rischio inaccettabile per la sicurezza per il soggetto;
    3. Presentare qualsiasi malattia concomitante che possa causare compromissione cognitiva non correlata a mutazioni nel gene GRN, come altre cause di demenza, neurosifilide, idrocefalo, ictus, malattia ischemica dei piccoli vasi, ipotiroidismo non controllato o carenza di vitamina
    4. Presentare un’anomalia clinicamente significativa alla RMI allo Screening che sia considerata una controindicazione all’infusione intratalamica;
    5. Presentare un pattern di atrofia cerebrale chirurgicamente significativo alla RMI allo Screening che, a giudizio del neurochirurgo, interferisce con la traiettoria neurochirurgica programmata;
    6. Precedente trattamento con qualsiasi terapia genica o cellulare;
    7. Precedente trattamento con qualsiasi prodotto medicinale sperimentale entro 60 giorni o 5 emivite (a seconda di quale periodo sia più lungo) prima del trattamento con il farmaco dello
    studio;
    8. Avere avuto una malattia concomitante, qualsiasi anomalia di laboratorio clinicamente significativa o trattamento che, a giudizio dello sperimentatore, potrebbe rappresentare un rischio inaccettabile per la sicurezza per il soggetto o interferire con la conduzione dello studio o con la capacità del soggetto di attenersi alle procedure dello studio;
    9. Aver avuto un tumore maligno nei 5 anni precedenti lo Screening, ad eccezione del carcinoma cutaneo basocellulare o a cellule squamose o del carcinoma della cervice in situ trattato con successo;
    10. Presentare eventuali controindicazioni alla RMI secondo le linee guida locali;
    11. Presentare controindicazioni agli agenti di contrasto a base di gadolinio in base alle linee guida locali;
    12. Presentare controindicazioni all’anestesia generale per un periodo massimo di 10 ore e/o disturbi cardiopolmonari che potrebbero comportare una classificazione del rischio maggiore
    secondo l’American Society of Anesthesiology (Società americana di anestesiologia);
    13. Presentare eventuali controindicazioni alla puntura lombare in base alle linee guida locali;
    14. Essere stati ricoverati in ospedale per qualsiasi procedura medica o chirurgica importante che preveda anestesia generale entro 12 settimane dallo Screening o di una procedura programmata durante lo studio;
    15. Attuale utilizzo di anticoagulanti allo Screening o necessità prevista durante il periodo di trattamento. Le terapie antipiastriniche sono terapie concomitanti accettabili se possono essere
    interrotte almeno 48 ore prima del trattamento;
    16. Presentare un’anamnesi di precedente malattia da coronavirus 2019 (COVID-19) grave o recente definita come (1) qualsiasi anamnesi di ricovero in ospedale per malattia grave in
    qualsiasi momento, (2) qualsiasi anamnesi di sintomi respiratori significativi in qualsiasi momento o (3) qualsiasi positività presintomatica o lievemente sintomatica alla COVID-19
    nelle 12 settimane precedenti il trattamento programmato;
    17. Presentare uno screening tossicologico positivo per le sostanze di abuso;
    18. Presentare un’anamnesi di disturbo da abuso di sostanze;
    19. Presenza di un dispositivo di stimolazione cerebrale profonda impiantato, shunt ventricoloperitoneale o altro shunt per liquido cerebrospinale o altro dispositivo impiantato;
    20. Presentare evidenza di rischio di suicidio, come valutato mediante la Scala della Columbia University per la valutazione della gravità del rischio di suicidio, definito come tentativo di suicidio nei 6 mesi precedenti lo screening o presentare un rischio significativo di suicidio secondo il giudizio dello sperimentatore; oppure
    21. Presentare un’intolleranza o ipersensibilità nota o sospetta al farmaco dello studio o a uno qualsiasi degli ingredienti indicati.
    E.5 End points
    E.5.1Primary end point(s)
    Over a 26-week initial and 5year total follow up period:
    • Number and incidence of AEs, SAEs, and clinically meaningful laboratory test abnormalities;
    • Change from baseline in vital signs, ECG parameters, and physical and neurological examinations, and MMSEChange from baseline in minimental state examination (MMSE);;
    • Change from baseline in clinical chemistry and hematology safety laboratory tests;
    • Time to achieve clearance of vector genomes in plasma and semen (male only)
    • Incidence of treatment emergent suicidal ideation or behavior as measured using the C-SSRS.
    • Change from baseline in MRI including oedema, inflammation, asymptomatic/symptomatic hemorrhage and other structural changes
    Nell’arco di un periodo di follow-up iniziale di 26 settimane e totale di 5 anni:
    • Numero e incidenza di EA, SAE e anomalie clinicamente significative degli esami di laboratorio;
    • Variazione rispetto al basale dei segni vitali, dei parametri ECG e degli esami obiettivi e neurologici, e variazione del MMSE rispetto al basale minimental state examination (MMSE)
    • Variazione rispetto al basale nei test di laboratorio per la sicurezza biochimica ed ematologica;
    • Tempo necessario per ottenere la clearance dei genomi vettoriali nel plasma e nel liquido seminale (solo negli uomini);
    • Incidenza di ideazione o comportamento suicidari emergenti dal trattamento misurata sulla scala C-SSRS; e
    • Variazione rispetto al basale nei risultati della RM, tra cui edema, infiammazione, emorragia presintomatica/sintomatica e altre variazioni strutturali.
    E.5.1.1Timepoint(s) of evaluation of this end point
    26 weeks and 5 years
    26 settimane e 5 anni:
    E.5.2Secondary end point(s)
    Over a 26-week initial and 5-year total follow up period:
    • Change from baseline in PGRN protein levels in CSF and blood;
    Over a 26-week initial and 5-year total follow up period:
    • Change from baseline in NfL levels in CSF and blood
    Over a 5-year follow up period:
    • Change from baseline in CDR+NACC FTLD-SB score;
    • Change in CGI C, PGI-C, CaGI-C
    Nell’arco di un periodo di follow-up iniziale di 26 settimane e totale di 5 anni:
    • Variazione rispetto al basale nei livelli di proteina PGRN nell’LCS e nel sangue.
    Nell’arco di un periodo di follow-up iniziale di 26 settimane e totale di 5 anni:
    • Variazione rispetto al basale nei livelli di NfL nell’LCS e nel sangue.
    Nell’arco di un periodo di follow-up di 5 anni:
    • Variazione rispetto al basale nel punteggio CDR+NACC FTLD-SB; e
    • Variazione di CGI-C, PGI-C e CaGI-C.
    E.5.2.1Timepoint(s) of evaluation of this end point
    26 weeks and 5 years
    26 settimane e 5 anni:
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis Yes
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans Yes
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    In Aperto
    Open
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA12
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United Kingdom
    United States
    Belgium
    France
    Italy
    Netherlands
    Poland
    Spain
    Sweden
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years6
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years6
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 5
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 4
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Participants will not be enrolled if they are unable to consent at initial screening/consent, but patients' disease may progress during the 5 year follow up period of the study, such that they will lack capacity to consent for themselves.
    I partecipanti non saranno arruolati se non sono in grado di acconsentire allo screening iniziale, ma la malattia può progredire durante il periodo di follow-up di 5 anni dello studio, in modo tale da non avere la capacità di acconsentire.
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state2
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 6
    F.4.2.2In the whole clinical trial 9
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Participants will receive their usual standard of care.
    I partecipanti riceveranno il loro consueto standard di cura.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2023-06-27
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2023-02-08
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 06:39:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA